Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), announced that it intends to offer and sell shares of its common stock in a public offering.
Nanosphere, Inc. (Nasdaq: NSPH) also announced that it intends to offer shares of its common stock in a public offering.
Alimera Sciences, Inc., (Nasdaq:ALIM) (Alimera) announced that will raise cash through a $40 million Series A Convertible Preferred Stock (Series A Preferred) financing.
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has submitted its responses regarding the ADASUVE Marketing Authorization Application (MAA) to the European Medicines Agency (EMA). Alexza expects to receive the Day 180 List of Outstanding Issues for the ADASUVE MAA in late September 2012. Alexza also announced today that it has completed the follow-up from the May 2012 EU Pre-Approval Inspection (PAI). This inspection resulted in no findings the EMA classified as Critical or Major deficiencies but resulted in 12 findings classified as Other and 4 recommendations.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) sad that it expects to release data from its Phase 2 trial of retaspimycin hydrochloride (HCl) in combination with docetaxel in patients with non-small cell lung cancer (NSCLC), during 1H 2013. They had originally planned to release data in 2H 2013. In addition, as noted in previous press releases, the company plans to initiate a Phase 2 trial of IPI-145 in patients with asthma as well as a Phase 2 trial in patients with rheumatoid arthritis in 2H 2012.
Novavax, Inc. (Nasdaq: NVAX) said it hopes to initiate a Phase 2 trial of RSV (respiratory syncytial virus) vaccine to protect infants through maternal immunization in low-resource countries, in women of childbearing age, during 2H 2012.